Cite

HARVARD Citation

    Ribrag, V. et al. (n.d.). An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013. Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record